The recognition of the pre-existing immune control by PKR with the identification of survivors with genetic defects in RPIA supports tolerance for short-term pharmaceutical targeting of the activity of the isomerase during the infection period (Huck et al, 2004; van der Knaap et al, 1999). The gene discussed is EIF2AK2; the disease is infection.